Free Trial

Mesoblast (NASDAQ:MESO) Shares Gap Up - Time to Buy?

Mesoblast logo with Medical background

Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $10.55, but opened at $11.23. Mesoblast shares last traded at $11.23, with a volume of 27,607 shares trading hands.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Cantor Fitzgerald upgraded Mesoblast to a "strong-buy" rating in a research note on Monday, March 31st. Piper Sandler reaffirmed an "overweight" rating and set a $24.00 price objective (up from $15.00) on shares of Mesoblast in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $18.00.

Read Our Latest Research Report on Mesoblast

Mesoblast Stock Up 1.6%

The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21. The firm's 50 day simple moving average is $11.10 and its two-hundred day simple moving average is $13.99.

Institutional Trading of Mesoblast

Institutional investors have recently modified their holdings of the stock. Barclays PLC bought a new position in shares of Mesoblast in the fourth quarter worth $38,000. Lindbrook Capital LLC grew its stake in Mesoblast by 70.9% during the fourth quarter. Lindbrook Capital LLC now owns 2,172 shares of the company's stock worth $43,000 after buying an additional 901 shares in the last quarter. JPMorgan Chase & Co. bought a new position in Mesoblast in the 4th quarter valued at about $50,000. BNP Paribas Financial Markets increased its holdings in Mesoblast by 86,566.7% in the 4th quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company's stock valued at $51,000 after buying an additional 2,597 shares during the period. Finally, Tower Research Capital LLC TRC acquired a new position in shares of Mesoblast in the 4th quarter valued at approximately $88,000. 1.43% of the stock is currently owned by institutional investors.

Mesoblast Company Profile

(Get Free Report)

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.

Featured Articles

Should You Invest $1,000 in Mesoblast Right Now?

Before you consider Mesoblast, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.

While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Congress Bought This Stock at the Bottom—Will You Miss It?
The Drone Industry Is About to 10X—Here’s How to Profit
Why AMD Stock Beats NVIDIA Right Now

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines